Introduction
============

Compared to open thoracotomy, video-assisted thoracoscopic surgery (VATS) provides lower-risk interventions with smaller skin incisions and no rib retraction. This reduces damage to the thoracic wall, offering the potential for reduced postoperative respiratory dysfunction and pain. Acute pain after VATS maybe severe, with potential to evolve into significant chronic pain.[@b1-lra-11-115],[@b2-lra-11-115] Optimal pain management strategies after VATS is controversial.[@b2-lra-11-115] The use of paravertebral block (PVB) may be preferred over epidural analgesia,[@b3-lra-11-115]--[@b8-lra-11-115] and some multimodal treatments have also shown excellent results.[@b9-lra-11-115],[@b10-lra-11-115]

A review of the literature from 2005 to 2015 suggests that thoracic PVB provides comparable analgesia to thoracic epidural analgesia (TEA) and, complemented with a pharmacological adjuvant, may represent a comparable alternative to TEA.[@b11-lra-11-115] Patient-controlled analgesia devices provide additional analgesia upon demand, and may be used to supplement paravertebral, epidural, or intravenous techniques.[@b12-lra-11-115],[@b13-lra-11-115]

Because intravenous patient-controlled analgesia (IVPCA) is less invasive, costly, and labor intensive than patient-controlled paravertebral analgesia (PCPA), it would be preferable if it has a similar analgesic effect and safety characteristics. We conducted this study to compare the efficacy and side effect profiles of IVPCA and PCPA for the management of postoperative pain after VATS lobectomy.

Patients and methods
====================

After obtaining approval from our institutional ethics committee (Military Hospital 103 Ethics Committee), 60 patients were enrolled in this randomized clinical trial. Patients classified as American Society of Anesthesiologist (ASA) physical status 1--3 underwent elective VATS lobectomy.[@b1-lra-11-115],[@b2-lra-11-115] Exclusion criteria included patient refusal to participate, age \<18 years, ASA physical status \>3, allergy to any of the study drugs, any contraindication to placement of PVB (severe coagulopathy, local infection, severe hypovolemia, untreated sepsis), preexisting chronic pain syndromes or chronic analgesic use, presence of acute herpes zoster, kyphoscoliosis, and psychiatric disease. All patients provided written informed consent, and the study was conducted in accordance with the Declaration of Helsinki.

Patients were thoroughly counseled about the procedures to be undertaken and the associated risks and benefits during a preoperative visit on the day before surgery. Each patient was instructed in how to evaluate his/her own pain using a visual analog scale (VAS) of 0--10 (0: no pain, 10: worst pain imaginable) and how to use a patient-controlled analgesia (PCA) device. Patients were directed to take 10 mg oral diazepam the night before surgery and to fast for a period of at least 6 hours prior to surgery.

A computer-generated table was used to randomly assign the patients into experimental (PCPA) and control (IVPCA) groups of 30.

After the application of standard monitors, including electrocardiography, noninvasive blood pressure (NIBP), and pulse oximetry, an intravenous saline infusion (8 mL/kg/h) was started. Pulse rate, peripheral arterial oxygen saturation (SpO~2~), NIBP, and respiratory rate were noted. Equipment for general anesthesia and resuscitation were kept ready.

General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 µg/kg of fentanyl, and 1.0 mg/kg of rocuronium. A double-lumen endotracheal tube was placed and appropriate position confirmed. Anesthesia was maintained with continuous infusion of propofol at the rate of 6--12 mg/kg/h, with 2 µg/kg of fentanyl and 0.15 mg/kg of rocuronium bloused every 30 minutes. After positioning patients in the lateral position, VATS was performed with one-lung ventilation.

In the PCPA group, paravertebral catheters (PVCs) were placed under sterile conditions upon completion of surgery. The upper edge of the spinous process of the thoracic vertebra (equidistant to the upper and lower intercostal space where ports had been placed) was recognized, and the needle insertion point was marked 2 cm lateral to the midline. Using a loss of resistance technique, the paravertebral space was entered by advancing a 22-G Tuohy epidural needle (B/Braun, Melsungen, Germany) over the superior border of the transverse process. Catheter was passed through the needle, and the needle was removed, leaving 3--5 cm of the catheter in the paravertebral space. Advancement of the needle and insertion of the catheter were verified continuously by the surgeon using the camera ([Figure 1](#f1-lra-11-115){ref-type="fig"}).

A test dose of 3 mL of 1.5% lidocaine with 1:200,000 epinephrine was administered to detect inadvertent intravascular placement of the catheter, suggested by an increase in heart rate or mean arterial pressure of \>20% above the baseline value within 60 seconds. After confirmation of a negative test dose, an initial bolus of 0.3 mL/kg of 0.125% bupivacaine with 2 µg/mL fentanyl was infused into the paravertebral space through the PVC ([Figure 2](#f2-lra-11-115){ref-type="fig"}).

After extubation, patients were encouraged to administer bolus doses of the same bupivacaine/fentanyl mixture via a PCA device (Perfusor Space; B/Braun). The device was programmed to provide a continuous infusion at 3 mL/h and to permit a 2 mL of demand bolus with a 10-minute lockout interval, limited to 25 mL over 4 hours.

In the IVPCA group, patients received morphine 1 mg/mL solution through PCA device. After extubation, we administered a 2 mL of bolus dose, supplemented with 1 mL every 3 minutes until VAS \<4. At this time, the PCA pump was programmed to permit a 1 mL demand bolus with a 10-minute lockout interval, limited to 20 mL over 4 hours. No basal infusion was provided.

In both the groups, if a patient was uncomfortable and reported a VAS \>4 after three consecutive demand boluses from the PCA, rescue analgesia of 0.5 µg/kg of IV fentanyl was provided. Chest drain with underwater seal drainages were removed when the patient condition was stable, radiological examination showed that the patient's lung got reinflated fully. And the volume of drainage was \<100 mL/24 h. After removing chest drainage tubes, pain management was remained with 500 mg paracetamol oral route every 6 hours if VAS score over 4.

The following outcomes were assessed: 1) the effect of pain control on postoperative days (PODs), 2) respiratory function (spirometry and arterial blood gas parameter), and 3) adverse events related to the analgesia technique, including respiratory depression (respiratory rate \<8 breaths/min), urinary retention, nausea, vomiting, headache, and pruritus.

SPSS v21 package (IBM Corporation, Armonk, NY, USA) was used for statistical data analysis. The patient characteristics between the two groups were compared using a Student's *t*-test. Adjustment of data sets to a normal distribution was always verified for the applicability of parametric statistics (Kolmogorov--Smirnov test). Subsequently, the comparison of serial measurement (variables) was performed by two-way ANOVA test.

Results
=======

Sixty patients with age from 32 to 72 years completed the study (30 in PCPA group, and 30 in IVPCA group). A successful PVB was achieved in all patients.

The demographic data of both the groups are shown in [Table 1](#t1-lra-11-115){ref-type="table"}.

Postoperative pain scores at rest were compared at 0, 2, 4, 8, 16, 24, 36, 48, and 72 hours. Statistically significant lower pain scores were observed in PCPA group as compared to IVPCA group ([Figure 3](#f3-lra-11-115){ref-type="fig"}). Pain scores on coughing were compared at 0, 2, 4, 8, 16, 24, 36, 48, and 72 hours. Statistically significant lower pain scores were observed in PCPA group as compared to the IVPCA group for the first 4 hours ([Figure 4](#f4-lra-11-115){ref-type="fig"}). The need for rescue analgesia via rescue boluses of intravenous fentanyl ([Table 2](#t2-lra-11-115){ref-type="table"}) was significantly lower in PCPA group (5 in PCPA group vs 44 in IVPCA group) (*P*\<0.001).

Compared to baseline values, postoperative FVC and FEV1 were reduced in both the groups at all time intervals. There were no significant differences between the groups ([Table 3](#t3-lra-11-115){ref-type="table"}). Arterial blood gas analysis demonstrated comparable pH, PaO~2~, and PaCO~2~ levels in both the groups throughout the study period ([Table 4](#t4-lra-11-115){ref-type="table"}). Oxygenation was satisfactory (PaO~2~ \>90 mmHg) in all patients during the study period in PCPA group. No patients in either group suffered respiratory depression ([Table 5](#t5-lra-11-115){ref-type="table"}).

The incidence of headache was higher in the IVPCA group (occur only at IVPCA group \[13.3%\]). Nausea and vomiting were experienced by 16.6% of patients in IVPCA group and 13.3% in PCPA group. Pruritis was experienced by 3.3% of patients in IVPCA group vs no patients in PCEA group ([Table 5](#t5-lra-11-115){ref-type="table"}).

Discussion
==========

We investigated whether postoperative pain management with PCPA has a superior benefits and risk profile compared to IVPCA in patients undergoing VATS. Patients with PCPA using fentanyl and bupivacaine as compared to IVPCA using morphine, following VATS lobectomy, had superior analgesia both at rest and during coughing, with a lower incidence of side effects.

Since it was first described in 1992,[@b14-lra-11-115] lobectomy via VATS has been increasingly performed as an alternative to resection by thoracotomy due to the minimally invasive nature of the procedure and its many advantages.[@b15-lra-11-115] We demonstrated that placement of a PVC under video guidance is a simple and safe technique, as previously shown by Karmakar.[@b16-lra-11-115] In our study, the success rate for PVC placement was 100%. The failure rate varies between 6.8% and 10% without the use of a support device technique.[@b17-lra-11-115],[@b18-lra-11-115]

Thoracic PVB provides effective post-thoracotomy analgesia, and the optimal way to deliver drugs into the paravertebral space is still being investigated.[@b19-lra-11-115] Single-shot preoperative PVB may represent an advantage over multiple-injection PVB in patients undergoing VATS.[@b20-lra-11-115],[@b21-lra-11-115] Results from a research of Català et al suggest that continuous thoracic paravertebral infusion provides better pain control than a bolus regimen.[@b22-lra-11-115]

The most remarkable result to emerge from the data is that VAS scores of PCPA group at rest and on coughing were lower than the IVPCA group. VAS scores on coughing group were variable between H48 and H72. This finding may be explained by after chest tube removal combined with the discontinuation of infusions (H72). In post-thoracic surgery analgesia, it is likely that complete pain control may not be achievable with a single agent or technique and that a balanced analgesic regime may be more appropriate. Some authors used IVPCA for post-thoracotomy and provided adequate analgesia effects with few side effects.[@b23-lra-11-115],[@b24-lra-11-115] Garutti et al showed that the use of PVCs provides excellent results in post-thoracotomy pain control.[@b25-lra-11-115] Several authors have demonstrated that a thoracic PVB before VATS provides excellent pain relief with few side effects during the first postoperative hours.[@b20-lra-11-115],[@b26-lra-11-115],[@b27-lra-11-115] In our study, PVCs with continuous infusions and patient-controlled boluses provide pain relief from completion of surgery until removal 3 days after surgery.

The principal benefit of PCA devices is individually titrated dosing to provide adequate analgesia, while reducing side effects and complications rate that might be caused by unnecessarily higher doses. The number of dermatomes affected by PVB has been studied by Cheema et al.[@b28-lra-11-115] Greater volumes of local anesthetic will extend blockade to more dermatomes and extend the analgesic effect. However, greater volumes carry a risk of reaching the epidural space through the lateral foramen, exposing patients to additional risks, including undesired vertical or contralateral spread.

Our results showed that a 0.3 mL/kg bolus of 0.125% bupivacaine with 2 µg/mL fentanyl achieved a satisfactory analgesic effect, with extensions to three dermatomes in 50% of patients, and four dermatomes in 40% of patients. The factors affecting the spread of bupivacaine in the thoracic paravertebral space have been studied by Cheema et al.[@b28-lra-11-115] The more the number of dermatome inhibition we had, the more analgesia efficacy it increases. But if drugs were too much, it will enter epidural space through lateral foramen and expose patients to additional risks. Our results showed that it achieved analgesia efficacy. Five patients required fentanyl injection to provide rescue analgesia in PCPA group; however, in these cases, the chest tube had been displaced by transport or sudden movement. The frequency of rescue analgesia was significantly lower in PCPA group, suggesting that PCPA provides more reliable and consistent analgesia than IVPCA.

Both open thoracotomy and VATS have the potential to severely compromise respiratory mechanics and gas exchange; in this respect, they are among the most damaging surgical insults a patient may receive.[@b29-lra-11-115],[@b30-lra-11-115] Post-thoracotomy pain discourages deep inspiration, and poor analgesia after thoracotomy can lead to impaired coughing, reducing the patient's ability to clear secretions, risking respiratory failure. Elsayed et al found a correlation between surrogate measures of pulmonary function and important outcome measures and that PVC use is associated with a shorter hospital stay (6 vs 7 days; *P*=0.008).[@b31-lra-11-115] We assessed spirometry results and arterial blood gas analysis to evaluate pulmonary function.

In both the groups, FVC and FEV1 had decreased significantly on POD 1 compared to baseline values. Both the groups recovered at comparable rates between POD 1 and POD 3. Improvement in spirometry over time after thoracic surgery is well described by other authors.[@b4-lra-11-115],[@b32-lra-11-115],[@b33-lra-11-115] Our results suggest that the benefits of IVPCA in terms of restoration of pulmonary function were equal to those of PCPA in patients undergoing VATS. Assessment of the effect of pain relief on spirometry is subject to some confounding factors, notably the possibility that the surgery itself might have altered lung volumes (eg, lobe resection, removal of mass effect). Other studies suggest that decreases in FVC and FEV1 to as little as 59%--64% of predicted values can be expected on POD 1,[@b34-lra-11-115] with recovery to 85%--90% by POD 7.[@b35-lra-11-115] Our patients demonstrated values of 41%--45% at POD 1 and showed improvement until POD 3. Because we did not measure spirometry after POD 3, further direct comparison with the above studies was not possible. The reason why we did not check the FVC and FEV1 after POD 3 is that we assumed that if there was a difference in pulmonary function recovery between the groups, it would appear in the acute postoperative period.

Arterial blood gas analysis showed that there were no significant differences between the two groups. pH and PaCO~2~ were in a normal range in both the groups. We did not show PaO~2~, and it can be explained by using oxygen support after surgery. Oxygen support depends on patient status. If we did not know how many patients get supplemental O~2~, then the average PaO~2~ measurements really do not mean anything. This analysis provides general looks, and it is about the analgesia effect on respiratory function, side effects, and complications. Clinicians can use it to make some changes in treatment strategies. Further study should be done to evaluate the variety of arterial blood gas after VATS procedure.

The complication rate was low. In our study, although there were slightly higher tendencies for nausea and vomiting in the IVPCA group, these differences were not significant. Other studies haves shown the same results.[@b36-lra-11-115]--[@b38-lra-11-115] Headaches were only noted to occur in the IVPCA group.

Conclusion
==========

PCPA is an effective technique to manage pain after VATS. The resulting analgesia is superior to the IVPCA regimen we tested. No patient in either group suffered significant complications, and recovery of postoperative respiratory function was similar between the groups. PCPA may be associated with fewer side effects than IVPCA.

One limitation of our study is that we have not followed up patients after their discharge from the hospital. Our findings are limited to the acute postoperative period.
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###### 

Demographics comparison of study groups

  Characteristics                      PCPA (n=30)          IVPCA (n=30)      *P*-value
  ------------------------------------ -------------------- ----------------- -----------
  Age (years)                          50.9±11.3            49.25±9.26        0.5386
  Sex (M/F)                            23/7 (76.6%/23.4%)   18/12 (60%/40%)   
  Weight (kg)                          56.68±9.78           52.13±6.2         0.0356
  Height (cm)                          163.64±7.73          162.18±7.82       0.47
  Operation time (min)                 175.36±42.39         189.64±18.92      0.0974
  Duration of chest tubes (days)       5.46±1.35            6.16±1.26         0.043
  Postoperative hospital stay (days)   13.43±6.96           15.06±8.27        0.411

**Notes:** Results are presented as mean ± SD, or as % of group total.

**Abbreviations:** IVPCA, intravenous patient-controlled analgesia; M/F, male/female; PCPA, patient-controlled paravertebral analgesia.

###### 

Characteristics of analgesia procedure

  Characteristics                           PCPA        IVPCA        *P*-value
  ----------------------------------------- ----------- ------------ -------------
  The number dermatome inhibition 1/2/3/4   1/2/15/12                
  Rescue analgesia                          5           44           **\<**0.001
  Bupivacaine consumption (mg)              304.7±8.3                
  Morphine consumption (mg)                             54.62±5.59   

**Abbreviations:** IVPCA, intravenous patient-controlled analgesia; PCPA, patient-controlled paravertebral analgesia.

###### 

FVC and FEV1 parameters

  Parameters (time)   FVC (L)     FEV1 (L)                                     
  ------------------- ----------- ----------- -------- ----------- ----------- --------
  Pre-operation       2.78±0.64   2.71±0.51   0.6412   2.12±0.66   2.07±0.52   0.7456
  POD 1               1.27±0.44   1.22±0.16   0.5609   0.88±0.31   0.87±0.14   0.8726
  POD 2               1.41±0.37   1.37±0.24   0.6212   1.05±0.27   1.01±0.17   0.4950
  POD 3               1.68±0.54   1.65±0.35   0.7994   1.29±0.47   1.25±0.25   0.6822

**Note:** Results are presented as mean ± SD.

**Abbreviations:** PCPA, patient-controlled paravertebral analgesia; IVPCA, intravenous patient-controlled analgesia; POD, postoperative day.

###### 

Arterial blood gas analysis

  Characteristics   Before operation   POD 1        POD 2        POD 3                                               
  ----------------- ------------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  PaCO~2~ (mmHg)    38.04±5.27         37.32±2.31   38.72±8.68   39.53±3.27   38.63±3.17   39.45±2.45   36.86±4.66   42.66±2.45
  pH                7.38±0.04          7.428±0.01   7.36±0.05    7.388±0.03   7.40±0.04    7.337±0.01   7.43±0.02    7.345±0.01

**Note:** Results are presented as mean ± SD.

**Abbreviations:** PVB, paravertebral block; IVPCA, intravenous patient-controlled analgesia; POD, postoperative day.

###### 

Side effects and complications

  Symptoms/signs                                       PVB, n=30   IVPCA, n=30   *P*-value
  ---------------------------------------------------- ----------- ------------- -----------
  Respiratory depression                               0           0             
  Nausea and vomiting                                  4 (13.3%)   5 (16.6%)     0.718
  Pruritus                                             0           1 (3.3%)      0.313
  Headache[a](#tfn9-lra-11-115){ref-type="table-fn"}   0           4 (13.3%)     0.038
  Urinary retention                                    0           0             

**Notes:** Results are presented as number ofpatients who experienced the side effect.

Incidence of headachewas statistically significantly higher in the IVPCA group.

**Abbreviations:** PVB, paravertebral block; IVPCA, intravenous patient-controlled analgesia.
